Pacific Biosciences of California, Inc. Deferred Sales Commission
Pacific Biosciences of California, Inc. (PACB) had Deferred Sales Commission of $200.00 thousand as of 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Notes › Revenue Recognition and Deferred Revenue › ASU 2014-09 Transition
us-gaap:DeferredSalesCommission · last filed 2018-08-03
- 2018-06-30: Deferred Sales Commission $200.00K.
- 2018-03-31: Deferred Sales Commission $200.00K.
| Period end | Deferred Sales Commission |
|---|---|
| 2018-06-30 | $200.00K 10-Q · filed 2018-08-03 |
| 2018-03-31 | $200.00K 10-Q · filed 2018-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B |